Internal Medicine, Endocrinology, Diabetes, & Metabolism · Lufkin, TX
NPI
1588665228
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
10 Medical Center Blvd, Suite A
Lufkin, TX, 75904
Phone (936) 632-4282
Groups this clinician bills Medicare through
Medicare paid, 2024
$152K
2,154 services
Medicare patients, 2024
472
Average age 71
Drug cost, 2024
$3.7M
7,428 prescriptions
Company payments, 2025
$237K
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lance A Sloan was code 99214 (office e&m - established), 469 times for 292 patients. In total Lance A Sloan billed 2,154 services in 37 codes, and Medicare paid $152K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 469 | 292 | $80.42 | $38K |
| 99215 Office E&M - Established | Office | 265 | 168 | $102.60 | $27K |
| 99213 Office E&M - Established | Office | 251 | 174 | $49.71 | $12K |
| 83036 Blood Count | Office | 166 | 121 | $9.25 | $1,536 |
| 99233 Hospital E&M - Subsequent | Facility | 128 | 39 | $82.52 | $11K |
| 99232 Hospital E&M - Subsequent | Facility | 80 | 31 | $55.75 | $4,460 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 56 | 55 | $11.71 | $656 |
| 96372 Injection Administration | Office | 55 | 17 | $9.48 | $521 |
| 99204 Office E&M - New | Office | 51 | 51 | $108.19 | $5,517 |
| G0008 Administration of influenza virus vaccine | Office | 46 | 46 | $31.03 | $1,427 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 42 | 37 | $21.90 | $920 |
| 90661 Vaccine Product | Office | 41 | 41 | $36.11 | $1,481 |
| G0009 Administration of pneumococcal vaccine | Office | 39 | 38 | $31.03 | $1,210 |
| 90677 Vaccine Product | Office | 39 | 38 | $289.49 | $11K |
| 99223 Hospital E&M - Initial | Facility | 38 | 33 | $122.57 | $4,658 |
By year: 2022 $229K for 2,768 services; 2023 $239K for 2,868 services; 2024 $152K for 2,154 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 166 | 121 | $9.25 | $1,536 |
Medicare prescription drug claims, 2024
In 2024, the drug Lance A Sloan prescribed most often to Medicare patients was Ozempic (Semaglutide), with 626 prescriptions and refills. In total Lance A Sloan wrote 7,428 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 626 | 836 | 160 | $787K |
| Atorvastatin Calcium Generic | 428 | 1,036 | 140 | $4,103 |
| Mounjaro Tirzepatide | 395 | 423 | 105 | $434K |
| Levothyroxine Sodium Generic | 383 | 766 | 113 | $3,132 |
| Synjardy Xr Empagliflozin/Metformin Hcl | 331 | 571 | 86 | $298K |
| Jardiance Empagliflozin | 224 | 434 | 70 | $238K |
| Xigduo Xr Dapaglifloz Propaned/Metformin | 216 | 350 | 57 | $185K |
| Farxiga Dapagliflozin Propanediol | 212 | 342 | 56 | $183K |
| Rosuvastatin Calcium Generic | 182 | 461 | 67 | $2,589 |
| Ramipril Generic | 158 | 362 | 51 | $1,243 |
| Tresiba Flextouch U-200 Insulin Degludec | 131 | 241 | 41 | $111K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 130 | 202 | 34 | $22K |
| Trulicity Dulaglutide | 113 | 123 | 34 | $117K |
| Torsemide Generic | 111 | 227 | 40 | $2,015 |
| Synthroid Levothyroxine Sodium | 108 | 204 | 31 | $7,026 |
Brand drugs: 3,686 claims; generic drugs: 3,524 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lance A Sloan $237K ($236K in general payments such as food, travel and fees and $985 for research) from 36 companies. The largest payer was Corcept Therapeutics with $81K.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 87 | $81K |
| Lilly USA, LLC LLY | 92 | $72K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 37 | $39K |
| Pfizer Inc. PFE | 12 | $11K |
| Sanofi-Aventis U.S. LLC SNY | 8 | $9,548 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 34 | $8,740 |
| Idorsia Pharmaceuticals US Inc | 2 | $4,093 |
| Madrigal Pharmaceuticals MDGL | 9 | $4,046 |
| Novo Nordisk Inc NVO | 22 | $3,062 |
| Travere Therapeutics, Inc. TVTX | 16 | $1,606 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.